Analysts think RVNC stock price could increase by 68%
Feb 11, 2025, 12:25 PM
0.00%
What does RVNC do
Revance Therapeutics, a clinical stage biotechnology company based in Nashville, develops novel botulinum toxin products, including DAXXIFY and the RHA Collection of dermal fillers. The company partners with Viatris and Fosun for biosimilar development and commercialization in China.
9 analysts think RVNC stock price will increase by 67.67%. The current median analyst target is $6.12 compared to a current stock price of $3.65. The lowest analysts target is $3.03 and the highest analyst target is $7.35.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
